The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage.

نویسندگان

  • Sophia Koo
  • Nils Kucher
  • Paul L Nguyen
  • John Fanikos
  • Peter W Marks
  • Samuel Z Goldhaber
چکیده

BACKGROUND We aimed to determine the effect of excessive anticoagulation on morbidity and mortality in hospitalized patients with major anticoagulant-associated hemorrhage. METHODS We prospectively identified 101 consecutive inpatients admitted to Brigham and Women's Hospital with major bleeding occurring during administration of warfarin sodium, unfractionated heparin (UFH), or low-molecular-weight heparin (LMWH). RESULTS Fifty patients had excessive and 51 had nonexcessive anticoagulation. The overall mortality at 60 days was 26% (13/50) in the excessive group compared with 10% (5/51) in the nonexcessive group (P =.03). Excessive warfarin therapy was associated with an increased 60-day mortality (P =.049), in contrast to excessive anticoagulation with UFH or LMWH alone (P =.27) or UFH or LMWH as a "bridge" to warfarin therapy (P =.10). Multivariate regression identified excessive anticoagulation as an independent predictor of 60-day mortality (adjusted hazard ratio [HR], 4.17; 95% confidence interval [CI], 1.39-12.49; P =.01), along with intracranial hemorrhage (adjusted HR, 6.16; 95% CI, 1.75-21.67; P =.005) and active cancer (adjusted HR, 3.79; 95% CI, 1.13-12.70; P =.03). Excessive anticoagulation was also a significant predictor of the combined nonfatal end point of stroke, myocardial infarction, hypotension, critical anemia, and surgical or angiographic intervention at 30 days (HR, 2.17; 95% CI, 1.25-3.78; P =.006). CONCLUSION In a cohort of patients with anticoagulation-associated hemorrhage, excessive anticoagulation contributed independently to increased morbidity and mortality.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Dabigatran etexilate - A novel oral anticoagulant for bleeding complications

Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabi...

متن کامل

The Effect of Adrenalin Administration on Circulation Stability in Massive Hemorrhage during Operations

Although occurance of sudden and extensive hemorrhage is not a new subject, however due to high morbidity and mortality a high level of experience and expertise is required to control the situation.Single adrenaline injction that is fast and very potent has been used in order to maintain BP and help the use of blood saved in other parts of the body.Durring 1375 to 1381 a total of 8 patients wer...

متن کامل

Challenging Management of Warfarinised Patients with Intracranial Hemorrhage Following a Head Injury: A Major Medical Dilemma

Introduction:The use of anticoagulant and ant platelet medications, especially warfarin and clopidogrel, is on a growing trend. Warfarin usage is commonly accompanied with hemorrhagic complications resulting in a noticeable mortality rate. Patient's ant coagulated with warfarin suffers from intracranial hemorrhage after a head injury. Materials and Methods: For the purpose of the study, the rel...

متن کامل

Anticoagulation Strategies for the Orthopaedic Surgeon: Reversal and Timelines

Article Highlights: 1) This article provides a full anticoagulant reference for the practicing orthopaedic surgeon which can be used in any clinical scenario, whether urgent or elective surgical intervention is required 2) A comprehensive list of anticoagulant reversal agents and drugs with short half-lives (for bridging) are described with the intention to provide the data needed t...

متن کامل

Comparative Efficacy of Meloxicam and Placebo in Vasospasm of Patients with Subarachnoid Hemorrhage

Cerebral vasospasm considered to be a serious cause of morbidity and mortality following subarachnoid haemorrhage (SAH).Despite several available therapeutic options, current protocols do not prevent major consequences of vasospasm. Inflammation is believed to play an important role in post-haemorrhagic vasospasm. Meloxicam is a non-steroidal anti-inflammatory drug. The aim of this study was to...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Archives of internal medicine

دوره 164 14  شماره 

صفحات  -

تاریخ انتشار 2004